Proteinase 3 Antibody, IgG
Antiproteinase 3 antibodies, also known as anti-neutrophil cytoplasmic antibodies or ANCA, are a type of autoantibody produced against several cytoplasmic proteins/antigens of neutrophils and monocytes. Among these antigens are Myeloperoxidase (MPO) and proteinase 3. These antibodies are mainly found in autoimmune diseases such as necrotizing vasculitis, Wegener’s granulomatosis, microscopic polyangiitis, kidney limited vaculitis, Churg-Strauss angiitis, drug induced vaculitis, and idiopathic crescentic glomerulonephritis. The antineutrophil antibodies are best demonstrated in this type of disease by using a combination of IFA and EIA testing that detect ANCA specific for PR3-ANCA or MPO-ANCA.
The presence of anti-MPO antibodies is associated with classic polyarteritis nodosa, idiopathic- and vasculitis-associated crescentic glomerulonephritis, polyangiitis overlap syndrome without renal involvement, and Churg-Strauss syndrome. The anti-PR3 antibodies are associated with Wegener granulomatous (WG) disease and the sensitivity is reported to be 98%. Some patients with WG have pANCA and MPO activity. Approximately 60% of patients with microscopic polyangiitis and pauci-immune segmental necrotizing glomerulonephritis have pANCA with MPO specificity. Only 30% have cANCA with PR3 specificity. The levels of anti-PR3 or anti-MPO are increased during the active phase of a disease and lower during remission. These can be monitored during the disease. MPO-ANCA vasculitis is characterized by necrotizing small-vessel vasculitis, in particular the kidney and lungs but other organ systems can be involved. These antibodies have been described in patients with other systemic autoimmune conditions including SLE, rheumatoid arthritis, antithyroid drug use, scleroderma, and inflammatory bowel disease.
- Diagnosis of Wegener’s granulomatosis
- In combination with anti-MPO ANCA, differentiating WG from microscopic polyarteritis (MPA)
- As an aid in evaluation for Goodpasture's Syndrome of lung hemorrhage and nephritis.
- In combination with cANCA test, useful to monitor effects of therapy
- Evaluating the possibility of relapse
Negative: <5 IU
Borderline: 5-15 IU
Positive: >15 IU
Serum (SST).
Stability
- Ambient: 5-7 days
- Refrigerated: 7-14 days
- Frozen: 30 days
- J Immunol. 2012 Sep 1; 189(5): 2574-83. [PMID: 22844112]
- J Autoim. 2008 Feb-March; 30(1-2): 29-36. [PMID: 18162369]
- Am J Kidney Dis. 1995; 25(3):380-9. [PMID: 7872315]
- Kidney Int. 2000 Jun;57(6):2195-206. [PMID: 10844589]
- Curr Opin Rheumatol. 1995; 7(1):11-9 (review). [PMID: 7718417]
- Am J Clin Pathol. 1999; 111(4):507-13. [PMID: 10191771]
- Clin Exp Immunol. 1999; 115:362–368. [PMID: 9933466]